


APPENDIX

Supplementary Figure 1. Androgen deprivation therapy (ADT) monotherapy flowchart. ODB: Ontario Drug Benefit; PC: prostate cancer.



Cheung DC, et al. Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologists

Supplementary Table 1. Factors associated with high mono-prescribers (80% cutoff) limited to ADT prescriptions filled after 2009				
Characteristic		OR	95% CI	p
Sex	Male	1.0		
	Female	0.68	0.07–6.29	0.7
Canadian medical graduate	No	1.0		
	Yes	0.53	0.20–1.41	0.2
Years in practice	Per year	1.06	1.03–1.10	0.0002
Institution type	Academic (ref)	1.0		
	Cancer center	1.16	0.38–3.54	0.8
	Community	0.67	0.32–1.38	0.3
Patient volume	Below median (ref)	1.0		
	Above median	0.44	0.21–0.90	0.024

CI: confidence interval; OR: odds ratio.

Supplementary Table 2. Characteristics of low and high mono-prescriber urologists (based on date of first prescription) (90% cutoff)			
Characteristic	Low mono-prescriber (<90%) n=246	High mono-prescriber (≥90%) n=36	p
Age (years), median (IQR)	39 (34–49)	58 (50–66)	<0.001
Sex, n (%)			0.3
Female	7 (2.9%)	0 (0%)	
Male	239 (97.2)	36 (100)	
Years in practice, median (IQR)	12 (7–22)	33 (21–40)	<0.001
Year of first prescription (year), median (IQR)	1999 (1997, 2005)	1998 (1997, 2002)	0.3
Number of patients per urologist, median (IQR)	76 (36–139)	32 (18–62)	<0.001
Canada medical graduate, n (%)			0.004
No	41 (16.7%)	13 (37.1%)	
Yes	204 (83.3%)	22 (62.9%)	
Type of institution, n (%)			0.5
Academic	71 (29.3%)	14 (38.9%)	
Regional cancer center	26 (10.7%)	≤5 (8.3%)	
Other	145 (59.9%)	19 (52.8%)	

IQR: interquartile range.

Cheung DC, et al. Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologists

Supplementary Table 3. Characteristics of patients^a of low and high mono-prescriber urologists (90% cutoff)			
Characteristic	Low mono-prescriber (<90%) n=246	High mono-prescriber (≥ 90%) n=36	p
Age (years), median (IQR)	75.9 (74.8–77.1)	76.3 (74.8–77.3)	0.4
ACG score, mean (SD)	9.5±0.8	9.4±1.0	0.4
ACG score, median (IQR)	9.5 (9.1–10.0)	9.4 (8.7–10.0)	0.4
Income quintile ^b , n (%)			0.007
2–2.5	49 (19.9%)	6 (16.7%)	
3–3.5	155 (64.0%)	22 (61.1%)	
4–4.5	41 (16.7%)	8 (22.24%)	
5	1 (0.4%)	0 (0.00%)	
Rural, n (%)			0.2
Yes	16 (6.5%)	5 (13.9%)	
No	230 (93.5%)	31 (86.1%)	

^aAverage of patients per physician to derive one value for each physician. ^bCategories are reported per physician (i.e., median income quintile (1–5) per patient was calculated and summated into the median patient-value per physician). ACG: Adjusted Clinical Groups; IQR: interquartile range; SD: standard deviation.

Supplementary Table 4. Factors associated with high mono-prescribers (90% cutoff)				
Characteristic		OR	95% CI	p
Years in practice	Per year	1.10	1.06–1.15	<0.0001
Institution type	Academic (ref)	1.0		
	Cancer center	0.58	0.13–2.58	0.5
	Community	0.45	0.19–1.08	0.075
Patient volume	Below median (ref)	1.0		
	Above median	0.30	0.13–0.74	0.009

CI: confidence interval; OR: odds ratio.

Cheung DC, et al. Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologists

Supplementary Table 5. Factors associated with high mono-prescribers (80% cutoff), including all medical specialties (n=407)				
Characteristic		OR	95% CI	p
Medical specialty	Urologist	1.0		
	Radiation oncologist	1.81	0.91–3.61	0.09
	Medical oncologist	0.76	0.29–1.96	0.6
Sex	Male	1.0		
	Female	1.46	0.60–3.54	0.4
Canadian medical graduate	No	1.0		
	Yes	0.83	0.45–1.53	0.5
Years in practice	Per year	1.06	1.03–1.08	<0.0001
Institution type	Academic (ref)	1.0		
	Cancer center	1.29	0.64–2.60	0.5
	Community	0.90	0.50–1.63	0.7
Patient volume	Below median (ref)	1.0		
	Above median	0.33	0.19–0.56	<0.0001

Overall p=0.15 for medical specialty; 0.67 for institution type. CI: confidence interval; OR: odds ratio.